Levetiracetam Injection
Product Images NDC 68083-153

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68083-153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Levetiracetam-spl-bag-1 (Levetiracetam Spl Bag 1)

Label for Levetiracetam Injection in 0.82% Sodium Chloride, 500 mg/100 mL (5 mg/mL), 100 mL single-dose dual port bag. For intravenous infusion only, infused over 15 minutes. Contains 500 mg Levetiracetam, sodium chloride, glacial acetic acid, and sodium acetate trihydrate. Manufactured by Gland Pharma Limited, Hyderabad, India. Storage at 20° to 25°C.*

FDA Label Image

Levetiracetam-spl-bag-2 (Levetiracetam Spl Bag 2)

Label for Levetiracetam Injection in 0.75% Sodium Chloride, 1000 mg per 100 mL (10 mg/mL) intravenous infusion. The label states infusion over 15 minutes, cautions about use of plastic containers and dilution, storage conditions at 20° to 25°C, and manufacturer Gland Pharma Limited, Hyderabad, India. Barcode and NDC 68083-153-01 are visible.*

FDA Label Image

Levetiracetam-spl-bag-3 (Levetiracetam Spl Bag 3)

Levetiracetam 15 mg/mL Injection in 0.54% Sodium Chloride, available as a 100 mL intravenous infusion. The label shows the strength as 1500 mg per 100 mL, intended for infusion over 15 minutes. Manufactured by Gland Pharma Limited, the single-dose dual port bag includes storage instructions at 20° to 25°C and cautions against dilution or use of plastic containers in series.*

FDA Label Image

Levetiracetam-spl-figure-1 (Levetiracetam Spl Figure 1)

A bar chart comparing the percentage of patients among three groups: Placebo (7.4%), Levetiracetam 1000 mg/day (37.1%), and Levetiracetam 3000 mg/day (39.6%). The chart indicates statistical significance of the Levetiracetam groups versus placebo.*

FDA Label Image

Levetiracetam-spl-figure-2 (Levetiracetam Spl Figure 2)

A bar chart depicting the percentage of patients in three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). Bars for both Levetiracetam groups indicate statistically significant differences versus placebo, as noted by asterisks and a footnote.*

FDA Label Image

Levetiracetam-spl-figure-3 (Levetiracetam Spl Figure 3)

A bar graph comparing the percentage of patients in two groups: Placebo (104 patients) showing 14.4%, and Levetiracetam 3000 mg/day (180 patients) showing 39.4%. The graph indicates that the difference is statistically significant versus placebo.*

FDA Label Image

Levetiracetam-spl-figure-4 (Levetiracetam Spl Figure 4)

A bar graph comparing the percentage of patients in two groups: placebo (N=84) and Levetiracetam (N=79). The placebo group shows 45.2% of patients, while the Levetiracetam group shows 72.2%, with a notation indicating statistical significance versus placebo. The vertical axis measures the percentage of patients from 0% to 100%.*

FDA Label Image

Levetiracetam-spl-structure (Levetiracetam Spl Structure)

Chemical structure of levetiracetam, showing a pyrrolidone ring attached to an ethyl group and an amide (CONH2) group, representing the active ingredient levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.